Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

This study has been terminated.
(Extreme toxicity of Pertuzumab and Erlotinib combination)
Genentech, Inc.
Information provided by (Responsible Party):
Pamela L. Kunz, Stanford University Identifier:
First received: July 23, 2009
Last updated: January 12, 2017
Last verified: January 2017
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).

Condition Intervention Phase
Neuroendocrine Tumors
Carcinoid Tumors
Adrenal Gland Tumors
Pancreatic Neuroendocrine Tumors
Multiple Endocrine Neoplasia
Drug: pertuzumab
Drug: erlotinib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Response Rate (RR) for All Patients Treated With This Strategy (Simon Design) [ Time Frame: CT scans are done every 4 cycles (every 12 wks) ]
    RECIST v1.1 used

Secondary Outcome Measures:
  • Toxicities Assessed by CTCAE Grading Criteria and Assigned Attributions Accordingly [ Time Frame: AEs are assessed every cycle (every 3 wks) ]
    by CTCAE

Enrollment: 4
Study Start Date: March 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pertuzumab and Erlotinib Drug: pertuzumab
840 mg, 420 mg, iv
Other Names:
  • 2C4
  • Omnitarg
  • Genentech
Drug: erlotinib
150 mg, PO
Other Names:
  • Tarceva
  • Erlotinib hydrochloride


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must be treated at Stanford University Medical Center for the entire length of study participation.

  1. Patients must have histologically or cytologically confirmed well-differentiated neuroendocrine tumor. Patients must be deemed unresectable due to involvement of critical vasculature or adjacent organ invasion or have metastatic disease.
  2. Patients with prior surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of > 5 years has elapsed between the primary surgery and the development of metastatic disease. Clinicians should consider biopsy of lesions to establish diagnosis of metastatic disease if there is substantial clinical ambiguity regarding the nature or source of apparent metastases.
  3. Prior chemotherapy will be permitted.
  4. Prior or concurrent somatostatin analogue use will be permitted.
  5. Patients must have a primary or metastatic lesion measurable in at least one dimension by Modified RECIST criteria (v1.1) within 4 weeks prior to entry of study.
  6. Patients must have ECOG performance status of 0-2.
  7. Patients must be >= 18 years of age.
  8. Laboratory values <= 2 weeks prior to randomization:

    • Absolute Neutrophil Count (ANC) >= 1.5 x 109/L (>= 1500/mm3)
    • Platelets (PLT) >= 50 x 109/L (>= 100,000/mm3) (or >= 25 x 109/L (>= 100,000/mm3) if thrombocytopenia is secondary to a non-myelosuppressive cause such as splenic sequestration).
    • Hemoglobin (Hgb) >= 9 g/dL
    • Serum creatinine <= 1.5 x ULN
    • Serum bilirubin <= 1.5 x ULN (<= 3.0 x ULN if liver metastases present)
    • Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) <= 3.0 x ULN (<= 5.0 x ULN if liver metastases present). Note: ERCP or percutaneous stenting may be used to normalize the liver function tests.
    • Albumin >= 1.5
  9. LVEF by TTE or MUGA >= 50%
  10. Life expectancy >= 12 weeks
  11. Ability to give written informed consent according to local guidelines

Exclusion Criteria:

  1. Disease-Specific Exclusions

    1. Prior full field radiotherapy <= 4 weeks or limited field radiotherapy <= 2 weeks prior to enrollment. Patients must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease.
    2. Prior biologic or immunotherapy <= 2 weeks prior to registration. Patients must have recovered from all therapy-related toxicities
    3. If history of other primary cancer, subject will be eligible only if she or he has:

      • Curatively resected non-melanomatous skin cancer
      • Curatively treated cervical carcinoma in situ
      • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last 3 years
    4. Concurrent use of other investigational agents and patients who have received investigational drugs <= 4 weeks prior to enrollment.
  2. General Medical Exclusions

    1. Subjects known to have chronic or active hepatitis B or C infection with impaired hepatic function (ineligible if AST and ALT > 3.0 x ULN).
    2. History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with study participation or study drug administration or may interfere with the conduct of the study or interpretation of study results
    3. Male subject who is not willing to use adequate contraception upon enrollment into this study and for 6 months following the last dose of second-line treatment
    4. Female subject (of childbearing potential, post-menopausal for less than 6 months, not surgically sterilized, or not abstinent) who is not willing to use an oral, patch or implanted contraceptive, double-barrier birth control, or an IUD during the course of the study and for 6 months following the last dose of second-line treatment
    5. Female subject who is breast-feeding or who has positive serum pregnancy test 72 hours prior to randomization
    6. Pleural effusion or ascites that causes respiratory compromise (>= CTCAE grade 2 dyspnea)
    7. Any of the following concurrent severe and/or uncontrolled medical conditions within 24 weeks of enrollment which could compromise participation in the study:

      • Unstable angina pectoris
      • Symptomatic congestive heart failure
      • Myocardial infarction <= 6 months prior to registration and/or randomization
      • Serious uncontrolled cardiac arrhythmia
      • Uncontrolled diabetes
      • Active or uncontrolled infection
      • Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
      • Chronic renal disease
    8. Patients unwilling to or unable to comply with the protocol
    9. Life expectancy of less than 12 weeks
    10. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored cancer study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00947167

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Pamela L. Kunz
Genentech, Inc.
Principal Investigator: Pamela Kunz Stanford University
  More Information

Responsible Party: Pamela L. Kunz, Assistant Professor, Stanford University Identifier: NCT00947167     History of Changes
Other Study ID Numbers: NET0008
16186 ( Other Identifier: Stanford IRB )
END0008 ( Other Identifier: Old OnCore Number )
Study First Received: July 23, 2009
Results First Received: January 12, 2017
Last Updated: January 12, 2017

Additional relevant MeSH terms:
Neuroendocrine Tumors
Carcinoid Tumor
Adenoma, Islet Cell
Multiple Endocrine Neoplasia
Endocrine Gland Neoplasms
Adrenal Gland Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
Adrenal Gland Diseases
Pertuzumab processed this record on April 24, 2017